Senti Biosciences, Inc.

As of August 13, 2024, Senti Biosciences, Inc. is considered overvalued at $1.99 due to negative financial metrics, including a Price to Book Value of 2.65, an EV to Capital Employed ratio of 8.02, and a year-to-date return of -43.3%, indicating significant operational inefficiencies and underperformance compared to its peers.

As of June 10, 2025, the technical trend has shifted to a moderately bearish stance, supported by bearish momentum in the MACD, declining daily moving averages, and confirmation from Bollinger Bands, alongside a weaker performance compared to the S&P 500.

Senti Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $14 million and a market cap of $72.51 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -139.41%.

As of Jun 18, Senti Biosciences, Inc. has a market capitalization of 72.51 million and reported net sales of 0.00 million with a net profit of -54.79 million over the last four quarters. The balance sheet shows shareholder's funds of 50.76 million and total assets of 97.84 million.